sRAGE plays a role as a protective factor in the development of PCOS by inhibiting inflammation

This study determined the effect of exogenous soluble receptor for advanced glycation end products (sRAGE) on the pro-inflammatory activities that occur during polycystic ovary syndrome (PCOS) in human follicular cells and explored a potential mechanism for preventing the development of inflammation...

Full description

Saved in:
Bibliographic Details
Published in:Gynecological endocrinology 2020-02, Vol.36 (2), p.148-151
Main Authors: Wang, Bi-Jun, Qian, Li, Li, Jing, Wang, Fang, Yang, Qing-Ling, Li, Gang, Liang, Yu-Ling, Guo, Yi-Hong
Format: Article
Language:English
Subjects:
inflammation
PCOS
reproduction
sRAGE
therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study determined the effect of exogenous soluble receptor for advanced glycation end products (sRAGE) on the pro-inflammatory activities that occur during polycystic ovary syndrome (PCOS) in human follicular cells and explored a potential mechanism for preventing the development of inflammation. Follicular fluid was allocated into one of three treatment groups (0, 0.6, and 1.2 μg mL −1 of sRAGE). Collectively, these results indicate that exogenous sRAGE supplementation alleviates inflammation in ovarian follicular granulosa cells by regulating p-ERK and AP-1 signaling.
ISSN:0951-3590
1473-0766
DOI:10.1080/09513590.2019.1633297